CRIS Current Research Information System

AZZAROLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.640
NA - Nord America 9.510
EU - Europa 6.769
AF - Africa 589
SA - Sud America 491
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 28.013
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.397
VN - Vietnam 3.836
SG - Singapore 2.615
CN - Cina 2.202
GB - Regno Unito 1.403
IT - Italia 1.357
DE - Germania 843
SE - Svezia 747
HK - Hong Kong 626
FR - Francia 437
IN - India 433
BR - Brasile 347
UA - Ucraina 338
RU - Federazione Russa 323
NL - Olanda 295
IE - Irlanda 286
KR - Corea 224
JP - Giappone 185
ZA - Sudafrica 161
CI - Costa d'Avorio 142
FI - Finlandia 142
EE - Estonia 106
CH - Svizzera 101
TG - Togo 92
SC - Seychelles 77
BG - Bulgaria 67
PH - Filippine 64
BD - Bangladesh 59
ES - Italia 58
TH - Thailandia 58
PL - Polonia 57
CA - Canada 55
AT - Austria 54
ID - Indonesia 50
AR - Argentina 48
NG - Nigeria 47
TR - Turchia 47
JO - Giordania 42
BE - Belgio 38
GR - Grecia 36
MX - Messico 33
EC - Ecuador 32
IQ - Iraq 29
TW - Taiwan 26
PK - Pakistan 25
SA - Arabia Saudita 24
IR - Iran 20
EG - Egitto 19
CO - Colombia 12
CZ - Repubblica Ceca 12
LT - Lituania 12
VE - Venezuela 12
AU - Australia 11
UZ - Uzbekistan 11
MY - Malesia 10
PE - Perù 10
PY - Paraguay 10
CL - Cile 9
LB - Libano 8
PT - Portogallo 8
TN - Tunisia 8
DK - Danimarca 7
HR - Croazia 7
IL - Israele 7
KE - Kenya 7
ET - Etiopia 6
MK - Macedonia 6
AE - Emirati Arabi Uniti 5
AO - Angola 5
BO - Bolivia 5
CR - Costa Rica 5
DZ - Algeria 5
JM - Giamaica 5
MA - Marocco 5
NP - Nepal 5
RO - Romania 5
RS - Serbia 5
DO - Repubblica Dominicana 4
KW - Kuwait 4
SI - Slovenia 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
CY - Cipro 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CM - Camerun 2
GH - Ghana 2
GN - Guinea 2
HN - Honduras 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LY - Libia 2
MD - Moldavia 2
MM - Myanmar 2
NI - Nicaragua 2
NO - Norvegia 2
Totale 27.985
Salva come PNG Salva come JPEG
Città #
Singapore 1.822
Southend 1.226
Fairfield 1.174
Ashburn 991
Ho Chi Minh City 944
Hanoi 827
Chandler 719
Hong Kong 569
San Jose 527
Santa Clara 411
Hefei 384
Wilmington 321
Bologna 320
Seattle 310
Princeton 306
Houston 300
Woodbridge 299
Dublin 283
Dong Ket 258
Beijing 237
Boardman 235
Cambridge 225
Jacksonville 203
Ann Arbor 186
Seoul 174
Lauterbourg 162
Dallas 161
Los Angeles 159
Da Nang 156
Tokyo 152
Abidjan 142
New York 140
Haiphong 124
Westminster 118
Nanjing 117
Milan 105
Council Bluffs 98
Padova 97
Frankfurt am Main 93
Berlin 92
Lomé 92
Buffalo 88
Helsinki 86
Bern 81
Munich 77
Medford 74
Saint Petersburg 72
Sofia 62
Rome 59
Biên Hòa 58
Jinan 58
Dearborn 57
Shanghai 56
Redondo Beach 52
São Paulo 51
Johannesburg 49
Shenyang 49
Hải Dương 48
Abeokuta 45
Hebei 45
Changsha 44
Thái Nguyên 43
Amman 42
Ha Long 42
San Diego 42
Can Tho 41
Guangzhou 40
Florence 39
Nanchang 39
Des Moines 37
Turin 37
Amsterdam 36
Orem 36
Bremen 35
Bắc Ninh 35
Mülheim 34
Bengaluru 33
Hangzhou 33
Quận Bình Thạnh 33
Redmond 33
Brussels 32
Falkenstein 32
Turku 32
Vienna 30
Vũng Tàu 30
Barcelona 29
Warsaw 29
Chicago 27
Tianjin 27
Bắc Giang 26
Bến Tre 26
Ninh Bình 26
Zhengzhou 25
Brooklyn 24
Lappeenranta 24
London 24
Mahé 24
Yubileyny 24
Bangkok 23
Phoenix 23
Totale 17.717
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 608
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 510
Outcomes and survival after TIPS positioning: a single center experience 403
Chronic non allergic rhinitis with neutrophilis (NARNE) and gastroesophageal reflux disease (GERD): A possible correlation? 352
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 335
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 303
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis 287
Monofocal hepatocellular carcinoma: How much does size matter? 283
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 275
Intrahepatic Cholestasis of Pregnancy: mRNAs for LIPF and ELOVL4 Genes Are Not Detectable in Circulating Maternal Plasma. 247
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 246
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 243
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 239
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 235
Pattern of macrovascular invasion in hepatocellular carcinoma 233
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 233
The future of dual therapy for hepatitis C virus 221
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 220
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 218
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 218
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 216
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 214
Adverse effects of proton pump inhibitors. 214
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 213
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 212
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis 208
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 208
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 207
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 205
The changing scenario of hepatocellular carcinoma in Italy: an update 200
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 198
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 197
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 196
Alisporivir for the treatment of chronic HCV 196
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 194
Sarcopenia predicts ascitic decompensation and mortality independently of portal hypertension status in patients with advanced chronic liver disease outside the liver transplantation setting 191
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 190
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 186
Utility of Doppler-Ultrasound and Liver Elastography in the Evaluation of Patients with Suspected Pregnancy-Related Liver Disease 185
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 185
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 185
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure 182
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib. 182
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 181
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 177
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 177
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 176
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 173
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 172
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 172
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 172
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 171
Pharmacological modulation of MRP2 in primary biliary cirrhosis 169
Terapia cellulare in Epatologia 168
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 167
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 167
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 166
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 163
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 163
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 162
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 162
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 162
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 161
Anorectal emergencies: WSES-AAST guidelines 161
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 160
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 158
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 156
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 156
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 156
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients 156
An unusual cause of weight loss in a young Caucasian man 155
Indocyanine green clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis. 155
Chemiluminescence measurement of autotaxin activity in human serum 154
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 154
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 154
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis 154
Indocyanine Green Clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis 154
Severe hypernatremia as a predictor of mortality after percutaneous endoscopic gastrostomy (PEG) placement 154
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 152
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 151
Fatty liver in pregnancy: a narrative review of two distinct conditions 151
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 150
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 150
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 149
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 149
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 149
Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests? 149
Reply 148
Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients 147
Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient 145
Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis 145
Graded pneumatic dilation in subtype I and II achalasia: long-term experience in a single center 145
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 144
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection 143
Extracorporeal shock wave lithotripsy for difficult common bile duct stones: a comparison between 2 different lithotripters in a large cohort of patients. 143
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. 142
UDCA UP-REGULATES HUMAN PLACENTAL BCRP EXPRESSION: PRELIMINARY RESULTS 141
The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis: Sarcopenia predicts ascites and death in cirrhotic patients 139
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations 138
Placental MRP2 is upregulated by UDCA in cholestasis of pregnancy. 137
Totale 19.398
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021675 0 0 0 0 0 0 0 0 0 74 86 515
2021/20223.261 220 101 160 187 245 144 82 187 137 172 1.173 453
2022/20233.101 343 429 170 380 212 236 114 159 524 98 239 197
2023/20241.030 68 146 54 120 94 225 41 69 63 63 40 47
2024/20254.044 165 616 378 224 610 203 292 127 79 364 211 775
2025/202611.132 1.945 945 931 677 1.090 545 1.559 435 2.229 776 0 0
Totale 28.486